Results 191 to 200 of about 72,920 (308)

GLP‐1 receptor activation attenuates chronic migraine‐like behaviour: Sex‐specific modulation of opioid‐ and endocannabinoid‐related pathways

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Chronic migraine (CM) is a highly disabling condition that remains suboptimally treated. Metabolic disturbances may trigger migraine chronification, whereas impaired endogenous pain inhibition contributes to CM development. Glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs), used for type 2 diabetes and obesity, show efficacy ...
Katarina Sićović   +6 more
wiley   +1 more source

From neuropeptides to toxins: illuminating the origins of venom complexity in cone snails. [PDF]

open access: yesMol Biol Evol
Koch TL   +12 more
europepmc   +1 more source

Cofactors in Anaphylaxis: Insights From the European Anaphylaxis Registry

open access: yesClinical &Experimental Allergy, EarlyView.
Forty‐nine per cent of reactions reported suspected cofactors (26% of children/adolescents, 59% of adults). Adjusted odds ratios for reaction severity increased with increasing number of suspected cofactors. Consistent effects for individual suspected cofactors were only observed for acute infections (children) and alcohol (adults with food‐induced ...
Margitta Worm   +13 more
wiley   +1 more source

Neural regulatory networks: challenges and opportunities in the treatment of psoriasis. [PDF]

open access: yesFront Immunol
Guo D   +9 more
europepmc   +1 more source

Structural and functional insights into rhodopsin‐like and secretin‐like GPCR–arrestin interactions and regulation

open access: yesThe FEBS Journal, EarlyView.
Distinct GPCR phosphorylation barcodes and arrestin conformational states direct arrestin‐mediated signaling and trafficking. The graphical abstract depicts the structural diversity of GPCR–arrestin complexes by overlaying representative core‐engaged and tail‐engaged conformations.
Varsha Gupta   +1 more
wiley   +1 more source

Real‐world outcomes of zavegepant use in a tertiary care setting using the Migraine Treatment Optimization Questionnaire‐5

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background The introduction of calcitonin gene‐related peptide antagonists has transformed migraine care. Zavegepant, a third‐generation intranasal gepant, offers a nonoral treatment option for acute migraine. Although clinical trials support its efficacy and safety, real‐world data are limited.
Eric Dunn   +5 more
wiley   +1 more source

Neuroimmune crosstalk in cancer: emerging immunotherapeutic opportunities. [PDF]

open access: yesJ Immunother Cancer
Dong T   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy